SGLT2 Inhibitors Are Lifesavers in Heart Failure - Heart Failure Clinics Skip to Main Content
Skip to Main Menu Advertisement Heart Failure Clinics Log in Register Log in Subscribe …

Despite continuous advances in both diagnosis and management, heart failure (HF) still
represents a major worldwide health issue. Recently, sodium-glucose co-transporter 2 …

Introduction: In individuals with type 2 diabetes mellitus, sodium–glucose cotransporter 2
(SGLT2) inhibitors reduce the risk of hospitalization for heart failure and serious adverse …

The totality of evidence from large-scale, randomized, controlled clinical trials and
mechanistic studies in the laboratory has provided six crucial lessons about the emerging …

Type 2 diabetes mellitus (T2DM) is a major risk factor for several cardiovascular (CV)
conditions, including heart failure (HF). However, until recently, no therapy to treat patients …

Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …

Background Heart failure (HF) prognosis without therapy is poor, however introduction of a
range of drugs has improved it. We aimed to perform a systematic review on the effects and …

Background Sodium-glucose co-transporter 2 (SGLT-2) inhibitors emerged as a new
groundbreaking therapy for patients with heart failure. Recent evidence showed significant …

Heart failure (HF) is a growing public health issue. As many as 1 in 5 people are expected to
develop HF during their lifetime, 1 with an estimated 63 million people affected worldwide. 2 …

Aims We sought to conduct a meta‐analysis regarding the safety and efficacy of sodium‐
glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and …